Literature DB >> 32727745

From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry.

Daan Marselis1, Lucien Hordijk1.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32727745     DOI: 10.1136/bmj.m2983

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

1.  How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.

Authors:  Abhimanyu Sud; Matthew Strang; Daniel Z Buchman; Sheryl Spithoff; Ross E G Upshur; Fiona Webster; Quinn Grundy
Journal:  BMJ Open       Date:  2022-07-12       Impact factor: 3.006

2.  A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland.

Authors:  Eeva Ollila; Vesa Kataja; Liisa Sailas
Journal:  J Pharm Policy Pract       Date:  2022-08-29

3.  Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.

Authors:  Paweł Żelewski; Michał Wojna; Katarzyna Sygit; Elżbieta Cipora; Izabela Gąska; Mateusz Niemiec; Mateusz Kaczmarski; Tomasz Banaś; Beata Karakiewicz; Artur Kotwas; Paulina Zabielska; Olga Partyka; Monika Pajewska; Edyta Krzych-Fałta; Ewa Bandurska; Weronika Ciećko; Aleksandra Czerw
Journal:  Int J Environ Res Public Health       Date:  2022-09-24       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.